The purpose of this study was to determine the effect of rbST treatment on progesterone concentration, volume of luteal tissue and pregnancy rate following embryo transfer. Recipient cows were assigned to control and rbST group, of which was given a single injection of rbST (500 mg. sc) at estrus detection. The concentration of progesterone was not significantly different between control and at 0, 3, 6 days after rbST treatment. However, the concentration of progesterone at 9, 12 days was significantly higher than in control group (4.6 and 6.8 vs. 3.9 and 4.5 ng/ml P4). The pregnancy rate after embryo transfer in rbST treatment was significantly higher than in control group (64.0 vs. 47.1 %; p<0.05). The results indicated that rbST treatment in recipient cows could be improved the efficiency of pregnancy rate after embryo transfer.
Major objective was to evaluate three doses of bST (POSILAC(R)) injected into Holstein cows during the transition period and through 56 d of lactation for potential to improve DMI, BCS, BW, metabolites, hormones, IGF-I and milk production. Biweekly injections of bST (0, 5.1, 10.2, or 15.3 mg bST/d) began 28 d before expected parturition and continued through 56 d postpartum. Twenty-three of the 25 multiparous Holstein cows assigned randomly to four groups completed experiment (7, 5, 6 and 5 cows/group, respectively). The DMI, BW and BCS were recorded weekly throughout the prepartum and postpartum periods and blood samples were collected thrice weekly for analyses of ST, insulin, $T_{4}$, $T_{3}$, IGF-I, glucose and NEFA. Milk yields were recorded daily through 60 d postpartum and milk components measured once weekly. Mathematical model for data analyses for prepartum and postpartum periods included treatment, calving month, and the two-factor interaction. Cows injected with 10.2 and 15.3 mg bST prepartum had greater mean prepartum concentrations of ST and IGF-I. Prepartum injections of bST did not affect prepartum BW or BCS. On average, cows injected postpartum better maintained their BCS during first 60 d of lactation (3.15$\pm$0.06, 3.12$\pm$0.007, 3.20$\pm$0.006 and 3.58$\pm$0.009). Treatments did not affect mean prepartum DMI but cows injected with 15.3 mg bST/d had greatest DMI and greatest mean daily MY during the first 3 wk and tended to be greater during first 60 d of lactation. Cows injected with two highest bST doses (10.1 and 15.2 mg/d) had greater mean postpartum concentrations of ST and $T_{3}$, but IGF-I, $T_{4}$, glucose and NEFA did not differ across groups. No adverse effects of bST treatment were observed.
Pregnant Yorkshire gilts were utilized to investigate the efficacy of exogenous administration of pST and/or insulin in enhancing prenatal piglet survival, uteroplacental and umbilical cord growth and development. Gilts were randomly assigned in a $2{\times}2$ factorial arrangement to four treatment combinations consisting of either daily i.m. injections of 5 mg pST (P, n=23); 0.50 IU/kg of insulin (I, n=23); combination of pST and insulin (P+I, n=23); or 1 ml of saline as control (C, n=23) from gestation Day 30 to 70. All gilts were sacrificed on gestation d 113 to evaluate piglet survival and uteroplacental or umbilical cord development Uteri were longer (346.3 vs 325.7 cm; p<0.05), and heavier (3122.8 vs 2940.7 g; p<0.05) in insulin treated gilts. Only placental macroscopic surface area was enhanced by maternal insulin injections (p<0.05) Incidence of umbilical cord abnormalities were low (14.3%), and they were independent of maternal treatment, occurring more in short cords than in long ones (21 vs 12%; p<0.05). A 6% increase in cord length (53.2 vs 48.6 cm; p=<0.05) was observed in piglets from treated gilts compared with controls. Significant sex differences (in favour of males) were observed in piglet weight, crown rump length and for most umbilical or placental parameters. Gilt weight gains from breeding to Day 113 of gestation were 10% and 15% greater in pST and insulin treated gilts compared with controls. These data indicate that prepartum injections of pST and/or insulin to gestating gilts seem to have a beneficial effect on uteroplacental or umbilical cord development and promote conditions conducive for perinatal piglet survival.
This study was carried out to investigate weight gain and prevention of diarrhea in suckling calves which were injected with recombinant bovine somatopropin (rBST). A total of 101 breeding cows were assigned to the six groups according to the administered dosage and injected time, respectively. Groups T-1, T-3, T-4 and T-6 were injected starting 1 week before calving and groups T-2 and T-5 were injected on the calving day. The six groups were injected five times at two week intervals. Groups T-1 and T-2 were injected with 250mg composite rBST, Group T-3 was injected with 375 mg composite rBST. Groups T-4 and T-5 were injected with 500mg composite rBST, And group T-6 was injected with 500mg rBST-S. The control group was not injected with BST. The groups injected with 500 mg BrST had a lower rate of morbidity from diarrhea than the control group or the groups injected with 250 mg rBST (T-1 and T-2). Weight gain was higher in group T-4 than in the control group or groups T-1 and T-2. In Korean Native Cattle, the total weight gain was greater in group T-4 than in the control group (p<0.05). In crossbred cows, total weight gain was the highest in group T-4, and the total weight gain rate was greater than in group T-4 and the control group (p<0.05). The results of the hematological values showed that injections of rBST did not affect the level of the RBC, TP and BUN in the breeding cows at 9 weeks after postpartum or the neonatal calves. The results of this study indicate that injecting breeding cows with 500 mg rBST before calving would be effective in the preventing of diarrhea and in increasing weight gain of calves from birth to weaning.
Kim, J.Y.;Cho, K.K.;Chung, M.I.;Kim, J.D.;Woo, J.H.;Yun, C.H.;Choi, Y.J.
Asian-Australasian Journal of Animal Sciences
/
v.15
no.4
/
pp.570-575
/
2002
Effects of active immunization against native 14-mer somatostatin (SRIF, somatotropin releasing inhibiting factor) and its two 14-mer-somatostatin analogues on the milk production in rat mammary cells were studied. Native SRIF, Tyr11-somatostatin (Tyr11-SRIF), and D-Trp8, D-Cys14-somatostatin (Trp8Cys14-SRIF) were conjugated to bovine serum albumin (BSA) for immunogen preparation. Twenty-four female Sprague-Dawley rats were divided into four groups and immunized against saline (Control), SRIF, Tyr11-SRIF, and Trp8Cys14-SRIF at five weeks of age. Booster immunizations were performed at 7, 9, and 11 weeks of age. SRIFimmunized rats were mated at 10 weeks of age. The blood and mammary glands were collected at day 15 post-pregnancy and -lactation. To measure the amount of milk protein synthesis in the mammary gland, mammary cells isolated from the pregnant and the lactating rats, were cultured in the presence of $^3H$-lysine. No significant differences in growth performance, concentration of growth hormone in the circulation, and the amount of milk protein synthesis were observed among the groups. Inductive levels of serum anti-SRIF antibody in the SRIF and Tyr11-SRIF groups but not in the Trp8Cys14-SRIF group, were significantly higher than that of the control group during the pregnancy and lactation periods. The result suggests that active immunization against native 14-mer SRIF and Tyr11-SRIF was able to induce anti-SRIF antibodies, but did not affect the milk protein synthesis.
The aim of this study was to evaluate the effect of recombinant bovine somatotropin (bST; Boostin-S, LG Chem) treatment with FSH (Super OV) or PMSG on superovulatory response for transvaginal ultrasound-guided oocyte retrieval (TVR) in calves. Eight Korean Native Cattle(KNC) heifer calves; 150 to 240 days old; were randomly assigned to four treatment groups: 1) FSH(75 mg); 2) FSH (75 mg) + bST(500mg) 3) PMSG(1;000 IU); 4) PMSG(1, 000 IU) + bST(500 mg). Experimental calves in group 1 (n=2) and 2(n=2) were weekly superovulated for 4 consecutive weeks with daily injection of FSH for 3days and the next day subjected to TVR session. Animals in group 3 (n=2) and 4(n=2) were weekly stimulated for 4 consecutive weeks with a single dose of 1, 000 IU PMSG. TVR was performed on 72 hours after PMSG injection. Calves in group 2 and 4 was received injection of 500 mg of bST every 10 days. At each TVR session, follicle number and size were recorded; the oocytes collected and graded according to cumulus and cytoplasm investment. Collected oocyte were determined viable oocyte according to morphological quality with granulation of oocyte and number and status of cumlulus cells. IVM and IVF were performed and assessed cleavage rate on day 3 after fertilization. A Sonovet 600(Medison, Co., Ltd) realtime ultrasound scanner with a 6.5 MHz convex transducer, fixed at the tip of 500 mm estended handle equipped with a needle guide was used in collecting oocyte. Differences between groups were analysed by chi-square test. The population of large follicle ($\geq$5 nun) and aspiration rate were not significant different among the 4 groups. But, the number of small follicles (<5 mm) and aspirated oocyte in the KNC calves treated with bST were 1.3~1.6 times higher than in KNC calves treat with FSH or PMSG alone. In conclusion, the administration of bST with FSH or PMSG at superovulation for TVR in calves was increase the nurnber of small follicle which was influenced the number of aspiratable follicle.
This study was performed to investigate the effects of recombinant BST formulation treatment on the milk yield, milk components, mastitis, and general cow health condition when the formulations of retinyl palmitate, cholecalciferol and rBST were administered after the peak period of milk production. The milk yields of treatment groups (Group I, II, III and IV) were increased from 21.5% to 29.0% than that of control group. There was significant difference in milk production between treatment group II, IV and control group (P<0.05). However, there was no significant difference in milk production between treatment group I, III and control group (P<0.05). And the addition of retinyl palmitate and cholecalciferol into rBST formulation did not increase the milk yield. The milk of treatment groups with sustained-release rBST did not show significant difference in milk components (milk fat, protein, lactose, and solid not fat). However, there were minor changes, primarily in fat content of milk, during the first few weeks of rBST administration. There was no incidence of clinical mastitis between rBST treatment groups and control group. Addition of high and medium concentration of retinyl palmitate and cholecalciferol into sustained-release rBST formulation was efficient in reduction of somatic cell count in milk. There was great energy deficit in all treatment groups compared with control group during the early study period. Thus, the body condition score of all treatment groups showed lower value than control group. No evidences of metabolic health problems, such as ketosis, milk fever, and downer cow were observed. Incidence of general lameness did not appear on all treatment groups during 140 days of this study.
Ko Y. M.;Kim D. W.;Kim K. E.;Shin S. C.;You S. J.;Ahn B. K.;Kang C. W.
Korean Journal of Poultry Science
/
v.31
no.4
/
pp.245-253
/
2004
This study was conducted to investigate the effects of dietary yeast culture containing rPST on growth performances and the characteristics of body compositions in broiler chickens. A total of 460 Ross male broiler chicks aged 2-day-old were fed one of five experimental diets; Control(devoid of all), TI (with $0.1\%$ antibiotics; chlorotetracycline), T2 (with $0.1\%$ rPST-yeast culture), T3 (with $0.2\%$ rPST-yeast culture) or T4 (with $0.2\%$ SC yeast culture) for 6 weeks. Feed consumption and body weights were measured weekly. At week 5 of the experiment, 10 chicks were randomly selected and sacrificed. The relative weights of each organ and the chemical composition of edible meat were measured. The enzyme activity, total cholesterol, Ca and P were also determined. Tibial weight, bone strength and chemical composition were investigated. There were no significant differences in feed intake and feed conversion ratios among the treatments throughout the experimental period. Body weight gains tended to be increased by feeding of diets containing rPST-yeast culture. The relative weight of breast muscle in T3 group was significantly higher than that of the control (P<0.05). The moisture contents of breast meat in groups fed diets containing rPST-yeast culture or SC yeast culture were significantly increased as compared with those of the control and n. However, the contents of crude protein and ether extract were not affected by feeding of rPST-yeast culture. There were no significant differences in GOT, total cholesterol, Ca and P. The relative weight and strength and proximal composition of the tibia were also not affected by dietary treatments. These results indicated that dietary rPST-yeast culture may be a valuable alternative for optimizing growth performances, particularly for improving the yield of breast muscle.
The purpose of this study was to examine the effect of growth hormone(GH) on the division and migration of the small intestinal epithelium in mice. Twenty mice(ICR), weighing initially about 10 g, aged 18 days were randomly subdivided in two groups of control and GH-treated group. Control group was sacrificied at 2 hr, 2, 3, 4 and 5 day after intraperitoneal injection of $^3H$-thymidine($^3H$-TdR, $4{\mu}$ Ci/gm of BW/day for 2 days). GH-treated group was injected subcutaneously with somatotropin(10 IU/mouse/day for 4 days) from 2 day ago of first $^3H$-TdR injection and then was sacrificied at 2 hr, 2, 3, 4 and 5 day after intraperitoneal injection of $^3H$-TdR($4{\mu}$ Ci/g of BW/day for 2 days). The small intestines were collected for autoradiogrophy and Hematoxylin counterstain. The location of the labeled epithelial cells(LEC) in villi of the small intestine was invested with light microscope. 1. In the control group, the LEC regions in the small intestine were located at crypts on 1 dsy, at $0%{\sim}15.9{\pm}3.6%$ of villus high value(VHV) on 2 day, at $0%{\sim}49.8{\pm}16.5%$ of VHV on 3 day, at $0%{\sim}95.3{\pm}6.9%$ of VHV on 4 day and $62.9{\pm}16.7{\sim}100%$ of VHV on 5 day, respectively. 2. In the GH-treated group, the LEC regions in the small intestine were located at crypts on 1 day, at $0%{\sim}39.2{\pm}9.5%$ of VHV on 2 day, at $0%{\sim}81.5{\pm}18.2%$ of VHV on 3 day, at $45.2{\pm}11.5%{\sim}100%$ of VHV on 4 day, at 85%~100% of VHV on 5 day, respectively. 3. VHV of tops in the LEC regions appeared to be 23.3% and 31.7% higher on 2 and 3 day, and VHV of the LEC region bases appeared to be 45.2%, 22.1% higher on 4 and 5 day, respectively in the GH-treated group than those observed in the control group. These difference was very highly significant(p<0.01).
This study was conducted to examine the effects of recombinant Bovine Somatotropin (rBST), vitamin E(Vit. E) and selenium (Se) administration on the blood chemical values and hormone concentrations of serum in Hanwoo sires. Hanwoo sires were randomly assigned to five groups; 1) control, 2) rBST,0.09mg/kg body weight (BW), 3) Vit E, 1,500IU/kg BW, 4) Se 0.1mg/kg BW, 5) Vit E, 1,500IU plus Se 0.1mg/kg BW. rBST, Vit. E and Se for each experimental group were given 6 times at 15 days interval by intermuscular injection. Blood samples were collected ten times for experimental periods and separated the serum by centrifugation and stored into deep freezer. The concentration of albumin was the highest in Se group than those of any other groups (P<0.05) and Vit. E plus Se group was significantly higher than in the control and rBST groups (P<0.05). The concentrations of blood urea nitrogen (BUN) and creatinine were significantly higher in rBST group than any other groups (P<0.05). The concentration of total protein in rBST, Se and Vit. E plus Se groups were significantly higher than in control group (P<0.05). The concentrations of calcium, cholesterol,, glucose, inorganic phosphorus and triglycerides in serum were not difference in all experimental groups (P>0.05). The concentration of estradiol was slightly higher in Se and Vit. E plus Se groups than those of any other groups, but not significantly difference among the experimental groups (P<0.05). The concentration of testosterone was not affected by the administration of rBST, Vit. E and Se.
본 웹사이트에 게시된 이메일 주소가 전자우편 수집 프로그램이나
그 밖의 기술적 장치를 이용하여 무단으로 수집되는 것을 거부하며,
이를 위반시 정보통신망법에 의해 형사 처벌됨을 유념하시기 바랍니다.
[게시일 2004년 10월 1일]
이용약관
제 1 장 총칙
제 1 조 (목적)
이 이용약관은 KoreaScience 홈페이지(이하 “당 사이트”)에서 제공하는 인터넷 서비스(이하 '서비스')의 가입조건 및 이용에 관한 제반 사항과 기타 필요한 사항을 구체적으로 규정함을 목적으로 합니다.
제 2 조 (용어의 정의)
① "이용자"라 함은 당 사이트에 접속하여 이 약관에 따라 당 사이트가 제공하는 서비스를 받는 회원 및 비회원을
말합니다.
② "회원"이라 함은 서비스를 이용하기 위하여 당 사이트에 개인정보를 제공하여 아이디(ID)와 비밀번호를 부여
받은 자를 말합니다.
③ "회원 아이디(ID)"라 함은 회원의 식별 및 서비스 이용을 위하여 자신이 선정한 문자 및 숫자의 조합을
말합니다.
④ "비밀번호(패스워드)"라 함은 회원이 자신의 비밀보호를 위하여 선정한 문자 및 숫자의 조합을 말합니다.
제 3 조 (이용약관의 효력 및 변경)
① 이 약관은 당 사이트에 게시하거나 기타의 방법으로 회원에게 공지함으로써 효력이 발생합니다.
② 당 사이트는 이 약관을 개정할 경우에 적용일자 및 개정사유를 명시하여 현행 약관과 함께 당 사이트의
초기화면에 그 적용일자 7일 이전부터 적용일자 전일까지 공지합니다. 다만, 회원에게 불리하게 약관내용을
변경하는 경우에는 최소한 30일 이상의 사전 유예기간을 두고 공지합니다. 이 경우 당 사이트는 개정 전
내용과 개정 후 내용을 명확하게 비교하여 이용자가 알기 쉽도록 표시합니다.
제 4 조(약관 외 준칙)
① 이 약관은 당 사이트가 제공하는 서비스에 관한 이용안내와 함께 적용됩니다.
② 이 약관에 명시되지 아니한 사항은 관계법령의 규정이 적용됩니다.
제 2 장 이용계약의 체결
제 5 조 (이용계약의 성립 등)
① 이용계약은 이용고객이 당 사이트가 정한 약관에 「동의합니다」를 선택하고, 당 사이트가 정한
온라인신청양식을 작성하여 서비스 이용을 신청한 후, 당 사이트가 이를 승낙함으로써 성립합니다.
② 제1항의 승낙은 당 사이트가 제공하는 과학기술정보검색, 맞춤정보, 서지정보 등 다른 서비스의 이용승낙을
포함합니다.
제 6 조 (회원가입)
서비스를 이용하고자 하는 고객은 당 사이트에서 정한 회원가입양식에 개인정보를 기재하여 가입을 하여야 합니다.
제 7 조 (개인정보의 보호 및 사용)
당 사이트는 관계법령이 정하는 바에 따라 회원 등록정보를 포함한 회원의 개인정보를 보호하기 위해 노력합니다. 회원 개인정보의 보호 및 사용에 대해서는 관련법령 및 당 사이트의 개인정보 보호정책이 적용됩니다.
제 8 조 (이용 신청의 승낙과 제한)
① 당 사이트는 제6조의 규정에 의한 이용신청고객에 대하여 서비스 이용을 승낙합니다.
② 당 사이트는 아래사항에 해당하는 경우에 대해서 승낙하지 아니 합니다.
- 이용계약 신청서의 내용을 허위로 기재한 경우
- 기타 규정한 제반사항을 위반하며 신청하는 경우
제 9 조 (회원 ID 부여 및 변경 등)
① 당 사이트는 이용고객에 대하여 약관에 정하는 바에 따라 자신이 선정한 회원 ID를 부여합니다.
② 회원 ID는 원칙적으로 변경이 불가하며 부득이한 사유로 인하여 변경 하고자 하는 경우에는 해당 ID를
해지하고 재가입해야 합니다.
③ 기타 회원 개인정보 관리 및 변경 등에 관한 사항은 서비스별 안내에 정하는 바에 의합니다.
제 3 장 계약 당사자의 의무
제 10 조 (KISTI의 의무)
① 당 사이트는 이용고객이 희망한 서비스 제공 개시일에 특별한 사정이 없는 한 서비스를 이용할 수 있도록
하여야 합니다.
② 당 사이트는 개인정보 보호를 위해 보안시스템을 구축하며 개인정보 보호정책을 공시하고 준수합니다.
③ 당 사이트는 회원으로부터 제기되는 의견이나 불만이 정당하다고 객관적으로 인정될 경우에는 적절한 절차를
거쳐 즉시 처리하여야 합니다. 다만, 즉시 처리가 곤란한 경우는 회원에게 그 사유와 처리일정을 통보하여야
합니다.
제 11 조 (회원의 의무)
① 이용자는 회원가입 신청 또는 회원정보 변경 시 실명으로 모든 사항을 사실에 근거하여 작성하여야 하며,
허위 또는 타인의 정보를 등록할 경우 일체의 권리를 주장할 수 없습니다.
② 당 사이트가 관계법령 및 개인정보 보호정책에 의거하여 그 책임을 지는 경우를 제외하고 회원에게 부여된
ID의 비밀번호 관리소홀, 부정사용에 의하여 발생하는 모든 결과에 대한 책임은 회원에게 있습니다.
③ 회원은 당 사이트 및 제 3자의 지적 재산권을 침해해서는 안 됩니다.
제 4 장 서비스의 이용
제 12 조 (서비스 이용 시간)
① 서비스 이용은 당 사이트의 업무상 또는 기술상 특별한 지장이 없는 한 연중무휴, 1일 24시간 운영을
원칙으로 합니다. 단, 당 사이트는 시스템 정기점검, 증설 및 교체를 위해 당 사이트가 정한 날이나 시간에
서비스를 일시 중단할 수 있으며, 예정되어 있는 작업으로 인한 서비스 일시중단은 당 사이트 홈페이지를
통해 사전에 공지합니다.
② 당 사이트는 서비스를 특정범위로 분할하여 각 범위별로 이용가능시간을 별도로 지정할 수 있습니다. 다만
이 경우 그 내용을 공지합니다.
제 13 조 (홈페이지 저작권)
① NDSL에서 제공하는 모든 저작물의 저작권은 원저작자에게 있으며, KISTI는 복제/배포/전송권을 확보하고
있습니다.
② NDSL에서 제공하는 콘텐츠를 상업적 및 기타 영리목적으로 복제/배포/전송할 경우 사전에 KISTI의 허락을
받아야 합니다.
③ NDSL에서 제공하는 콘텐츠를 보도, 비평, 교육, 연구 등을 위하여 정당한 범위 안에서 공정한 관행에
합치되게 인용할 수 있습니다.
④ NDSL에서 제공하는 콘텐츠를 무단 복제, 전송, 배포 기타 저작권법에 위반되는 방법으로 이용할 경우
저작권법 제136조에 따라 5년 이하의 징역 또는 5천만 원 이하의 벌금에 처해질 수 있습니다.
제 14 조 (유료서비스)
① 당 사이트 및 협력기관이 정한 유료서비스(원문복사 등)는 별도로 정해진 바에 따르며, 변경사항은 시행 전에
당 사이트 홈페이지를 통하여 회원에게 공지합니다.
② 유료서비스를 이용하려는 회원은 정해진 요금체계에 따라 요금을 납부해야 합니다.
제 5 장 계약 해지 및 이용 제한
제 15 조 (계약 해지)
회원이 이용계약을 해지하고자 하는 때에는 [가입해지] 메뉴를 이용해 직접 해지해야 합니다.
제 16 조 (서비스 이용제한)
① 당 사이트는 회원이 서비스 이용내용에 있어서 본 약관 제 11조 내용을 위반하거나, 다음 각 호에 해당하는
경우 서비스 이용을 제한할 수 있습니다.
- 2년 이상 서비스를 이용한 적이 없는 경우
- 기타 정상적인 서비스 운영에 방해가 될 경우
② 상기 이용제한 규정에 따라 서비스를 이용하는 회원에게 서비스 이용에 대하여 별도 공지 없이 서비스 이용의
일시정지, 이용계약 해지 할 수 있습니다.
제 17 조 (전자우편주소 수집 금지)
회원은 전자우편주소 추출기 등을 이용하여 전자우편주소를 수집 또는 제3자에게 제공할 수 없습니다.
제 6 장 손해배상 및 기타사항
제 18 조 (손해배상)
당 사이트는 무료로 제공되는 서비스와 관련하여 회원에게 어떠한 손해가 발생하더라도 당 사이트가 고의 또는 과실로 인한 손해발생을 제외하고는 이에 대하여 책임을 부담하지 아니합니다.
제 19 조 (관할 법원)
서비스 이용으로 발생한 분쟁에 대해 소송이 제기되는 경우 민사 소송법상의 관할 법원에 제기합니다.
[부 칙]
1. (시행일) 이 약관은 2016년 9월 5일부터 적용되며, 종전 약관은 본 약관으로 대체되며, 개정된 약관의 적용일 이전 가입자도 개정된 약관의 적용을 받습니다.